The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029. ...

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Item 1 of 2 A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid[1/2]A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New Y ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company†), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company's U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and ne. ...

Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy? - 24/7 Wall St.[S&P 5006,863.00 +0.16%][Dow Jones49,611.00 +0.09%][Nasdaq 10024,778.20 +0.23%][Russell 20002,649.42 +0.06%][FTSE 10010,678.40 +0.99%][Nikkei 22557,198.00 +0.25%][Investing]# Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?### Quick ReadVerizon (VZ) offers a 5.8% yield but carries $158B in debt. Johnson & Johnson (JNJ) provides a 2.1% yield with stronger growth.Verizon's dividend grew 2.04% ...

RYBREVANT FASPROâ"¢ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer [Accessibility Statement] Skip NavigationNew designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPROâ"¢ beyond lung cancerRARITAN, N.J., Feb. 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA ...

AC Immune (ACIU) has disclosed that its partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ) has temporarily paused enrollments in a mid-stage trial for their jointly developed Alzheimer’s candidate ACI-35.030/JNJ-2056. The companies are advancing ACI-35.030/JNJ-2056 as part of a licensing ...

Financial Data and Key Metrics Changes - Total revenue for 2025 grew by 38% to $1.4 billion, with royalty revenue increasing by 52% to $868 million, reflecting strong performance from ENHANZE-enabled products [9][17] - Net income for the full year was $316.9 million, down from $444.1 million in 2024, impacted by a $285 million acquired IP R&D expense [19] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024, indicating operational strength despite the IP charge [19] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10] - PHESGO's royalty revenue increased by 51% to $105.6 million, with total sales growing 48% year-over-year to approximately $3 billion [11] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12] Market Data and Key Metrics Changes - ENHANZE now has 10 global blockbuster opportunities, with significant approvals in the U.S., Japan, and China for various products [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13] Company Strategy and Development Direction - The company aims to expand its ENHANZE pipeline, projecting 6 new programs to enter phase one in 2026, bringing the total development portfolio to 15 products [24] - The strategy includes pursuing additional licensing agreements and evaluating new drug delivery technologies to enhance long-term revenue streams [27][28] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, emphasizing the durability of royalty revenue and the potential for exceptional value creation [23] - The company anticipates continued strong growth driven by existing products and new collaborations, with a focus on expanding into new therapeutic areas [25][36] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities and extending IP into the mid-2040s [6][27] - The balance sheet was strengthened with the issuance of convertible notes and an upsized revolving credit facility, reducing near-term refinancing risk [21] Q&A Session Summary Question: Regarding the DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42] Question: On the ADC strategy and regulatory paths - The regulatory pathway for converting ADCs from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, with additional trials for unapproved products [50] Question: Update on Hypercon products and clinical testing - Two Hypercon products are on track for phase 1 clinical testing in 2026, with completion of clinical scale-up batches and IND filings underway [66] Question: Potential incremental royalty opportunities from Merus's petosemtamab - Management highlighted the potential for expanded indications and the importance of subcutaneous formulations in enhancing patient treatment experiences [58]

Halozyme Therapeutics (NasdaqGS:HALO) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsChris Wahl - Chief Scientific OfficerHelen Torley - President and CEOJason Butler - Managing Director of Biotechnology Equity ResearchMichael DiFiore - Managing Director of Biotechnology and PharmaceuticalsMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchNicole LaBrosse - CFOSean Laaman - Executive Director and Head of U.S. SMID Cap Biotechnology ResearchTram Bui - VP of Investor ...

Bank of America Tumbles 7% While Verizon, J&J, and Chevron Rally on Dividend Hikes - 24/7 Wall St.[S&P 5006,801.80 -0.56%][Dow Jones49,329.10 -0.43%][Nasdaq 10024,497.10 -0.74%][Russell 20002,632.56 -0.25%][FTSE 10010,492.20 +0.22%][Nikkei 22556,578.00 -0.35%][Investing]# Bank of America Tumbles 7% While Verizon, J&J, and Chevron Rally on Dividend Hikes### Quick ReadPremarket activity shows that investors will be rotating into safer blue chips once trading opens this week. Johnson & Johnson (J&J), Chevron ( ...

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]